April 29, 2024 02:00 AM Eastern Daylight Time
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
View Full Size
Download
Full Size
JPEG, 1772x1749, 373.2 KB
Small
JPEG, 480x474, 93.7 KB
Preview
JPEG, 144x142, 39.5 KB
Thumbnail
JPEG, 71x70, 30.7 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: ENHERTU® Demonstrated Statistically Significant...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire